Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Dare Bioscience, Inc. (DARE) reported a Q3 loss of $0.55 per share, which was better than the Zacks Consensus Estimate of a $0.60 loss. However, the company lagged in revenue estimates.
November 14, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Dare Bioscience reported a Q3 loss of $0.55 per share, better than expected but still lagging in revenue estimates.
The company's loss per share was better than expected, which is a positive sign, but missing revenue estimates could offset this positive impact. The stock price may not see significant movement as the positive and negative news may balance each other out.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100